April 28, 2020 / 5:33 AM / a month ago

BRIEF-Roche Gives Update On Ocrevus Studies

April 28 (Reuters) - Roche Holding AG:

* NEW 6-YEAR DATA FOR ROCHE’S OCREVUS (OCRELIZUMAB) SHOW EARLIER TREATMENT INITIATION NEARLY HALVES RISK OF NEEDING WALKING AID IN RELAPSING MULTIPLE SCLEROSIS

* POST-HOC ANALYSIS FROM 6 YEARS OF PHASE III OPEN-LABEL EXTENSION STUDIES

* POST-HOC ANALYSIS FROM 6 YEARS OF PHASE III OPEN-LABEL EXTENSION STUDIES SHOWED OCREVUS TREATMENT REDUCED RISK OF NEEDING A WALKING AID

* SEPARATE ANALYSIS SHOWED OCREVUS SLOWED THALAMIC VOLUME LOSS IN PATIENTS WITH RMS AND PRIMARY PROGRESSIVE MS (PPMS) VERSUS. INTERFERON BETA-1A AND PLACEBO, RESPECTIVELY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below